Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, 2-Part Study to Evaluate the Effect of Food on Pharmacokinetics of Pelabresib (CPI-0610) and the Effect of Pelabresib on QTc in Patients With Advanced Malignancies

NCT05391022 is registered in ClinicalTrials.gov with Constellation Pharmaceuticals as lead sponsor.

NCT NCT05391022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05391022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, 2-Part Study to Evaluate the Effect of Food on Pharmacokinetics of Pelabresib (CPI-0610) and the Effect of Pelabresib on QTc in Patients With Advanced Malignancies
Lead sponsor
Constellation Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
July 20, 2021
Completion date
February 29, 2024
Enrollment
35 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies, hematological malignancy, solid tumor